• Recruiting

NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma

Updated: Sep 16

Talquetamab Phase 1b study

Phase 1 - Talquetamab in Multiple Myeloma

NCT05050097: phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

 

Sponsor

Janssen Research & Development, LLC


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT05050097

Official Title: A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

First Posted : September 20, 2021

Click here to see details on ClinicalTrials.gov


A Study of Talquetamab with Other Anticancer Therapies in Participants with Multiple Myeloma | Global Trial Finder (janssen.com)

 

JNJ-64407564 - Talquetamab


Treatment Regimen A: Talquetamab + Carfilzomib

Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib

Treatment Regimen C: Talquetamab + Lenalidomide

Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide

Treatment Regimen E: Talquetamab + Pomalidomide

 

Drug: Talquetamab (SC)

bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D)

JNJ 64407564

 

Drug: Carfilzomib ( Kyprolis)

Drug: Daratumumab SC ( DARZALEX FASPRO)

Drug: Lenalidomide (Revlimid)

Drug: Pomalidomide (Pomalyst)

 

- Multiple locations

- International study

 

- Alabama: University of Alabama at Birmingham

- California: University of California San Francisco

- Colorado: Sarah Cannon/Colorado Blood Cancer Institute Denver

- Georgia: Emory University Atlanta

- Indiana: Indiana University Indianapolis

- New Jersey: Hackensack University Medical Center

- New York: Tisch Cancer Institute Mount Sinai Hospital New York

- New York: New York Presbyterian / Weill Cornell Medical College New York

- North Carolina: Levine Cancer Institute Charlotte

- Pennsylvania: University of Pittsburgh Medical Center

- Tennessee: Sarah Cannon Research Institute Nashville

- Wisconsin: Medical College Of Wisconsin Milwaukee

 

Locations

United States, Alabama

United States, California

United States, Colorado

United States, Georgia

United States, Indiana

United States, New Jersey

United States, New York

United States, North Carolina

United States, Pennsylvania

United States, Tennessee

United States, Wisconsin


Europe

United Kingdom

France

Netherlands

Belgium

Australia

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)

Click here for details


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)

Click here for details


NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)

Click here for details


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)

Click here for details


CT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma

Click here for details


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

Click here for details

 

TALQUETAMAB STUDIES:


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1

Click here for details


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma

Click here for details


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

Click here for details

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma

Click here for details


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2

Click here for details